Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis’ Japan Sales Jump to 330.5 Billion Yen on Alcon Integration
April 15, 2020
- Lilly’s Japan Sales Grow 4.5% to 275 Billion Yen in 2019
April 15, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
- Shionogi Aiming at Clinical Trials of COVID-19 Treatment Candidates in FY2020
April 15, 2020
- Peptide Institute Latest to Chip In with AnGes to Develop Novel Coronavirus Vaccine
April 15, 2020
- Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
April 15, 2020
- Sosei Kicks Off COVID-19 Drug Discovery Program
April 15, 2020
- Sanofi Files Sutimlimab for Cold Agglutinin Disease in Japan
April 14, 2020
- Opdivo Adds New Indication for Esophageal Cancer in South Korea
April 14, 2020
- Tokushukai Preparing Model Formulary for 72 Group Hospitals; PPIs, Flu Drugs Eyed
April 14, 2020
- Daiichi Sankyo, Nagoya Institute of Technology, Mitsubishi UFJ Capital Pair Up on Research for Vision Restoration Gene Therapy
April 14, 2020
- Daiichi Sankyo Staffer in Toyama Infected with Coronavirus
April 14, 2020
- Healios to Enroll COVID-19 Patients in PII Off-the-Shelf Cell Therapy Program for ARDS
April 14, 2020
- Shimadzu to Roll Out Coronavirus Detection Regent Kit on April 20
April 14, 2020
- After Valsartan, Towa Now Curbing Clindamycin Supplies as India Lockdown Continues
April 13, 2020
- Astellas’ AML Drug Xospata Accepted for Review in China
April 13, 2020
- Chugai Shifting Resources to Beef Up Drug Discovery Prowess: New Chief
April 13, 2020
- Manufacturer Restresses Caution against BCG Vaccine’s Off-Label Use for COVID-19
April 10, 2020
- Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…